Investegate |Faron Pharma Oy Announcements | Faron Pharma Oy: Result of AGM investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Why are you making commenting on The National only available to subscribers? We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions. What should we do with our second vote in 2021? What happens if Westminster says no to indyref2? Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversation, register under fake names, and post vile abuse. We’ve had hundreds of emails from you complaining about this, asking us to take steps to ensure that these people aren’t given a platform on our site.
By Victoria Masterson A SPIN-OUT from the University of Edinburgh has raised £1 million to develop a new device that could “revolutionise” the early diagnosis and monitoring of difficult to detect cancers, such as kidney, thyroid and brain cancer. BioCaptiva raised the seed investment from business angel syndicate, Archangels, and economic development agency Scottish Enterprise for its ‘BioCollector’ device. The company says this overcomes “significant limitations” of current liquid biopsy testing – where blood is analysed for cells from cancerous tumours. “We are confident that this platform technology can make a significant impact in this important area and, ultimately, enable cancers to be detected more quickly and accurately, enabling patients to receive precision cancer treatment as early as possible,” said BioCaptiva chief executive Jeremy Wheeler.
Transcript: William J Bernstein - The Big Picture ritholtz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ritholtz.com Daily Mail and Mail on Sunday newspapers.
· EBITDA at £6.7m (2019 restated : £1.7m) · Profit before taxation of £4.5m (2019 restated profit : £1.1m) · Profit after taxation of £3.9m (2019 restated profit : £1.3m) · Earnings per share of 3.13p (2019: restated Earnings per share : 1.68p) · Cash generated by operations of £3.5m (2019 restated : £1.3m) · Net cash at 30th September 2020 of £12.9m (2019: £13.4m) Prior period figures have been restated to reflect adjustments arising from the March 2020 audit. Operations · USA recovery following the easing in geopolitical trade tensions between China and the USA · Latin America performing strongly, led by Brazil · New marketing authorisation from the European Medicines Agency for the use of Aivlosin® 625 mg/g Water Soluble Granules in pigs for the treatment of Mycoplasma hyopneumoniae